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The challenges of endocrinology, including those of endocrine disruption, force today’s 
medical science to face the numerous environmental health risks. Disruption of the endocrine 
system, which in reality affects the unity of the psycho-neuroendocrine immune system, may 
play a role in the development of many diseases. In this work, one of the basic questions was 
whether the environmental loads can cause disease (transformation disorders and processes) 
in the thyroid gland. Our aim was to develop the novel diagnostic method or environment-
related thyroid diseases. The endocrine disrupting compounds play an important role in 
inflammation and transformation of the thyroid gland. For this reason, upgrading any 
diagnostic method by adding environmental parameters is advised. 
 
Introduction 
The problem area of endocrine disruption in the introduction suggests that today's medical 
science, including the challenges of endocrinology [1] have to face numerous environmental 
health risks [2]. Disruption of the endocrine system, which actually affects the unity of the 
psycho-neuroendocrine immune system, may play a role in the development of many 
diseases. Thus, exploring the changing environmental conditions in the living spaces provided 
by society and the examining of the relationships among the health problems posed by those 
exposures can help us study the pathogens and pathomechanisms of certain systemic diseases.  
In the last half century, endocrine disruptors (ED) have caused very serious dysfunctions in 
the endocrine glands, especially in the thyroid [3], which have led to severe functional 
variations. For diseases with thyroid proliferation [4] it is a major health and therapeutic 
question whether the benign and/or malignant thyroid diseases should be considered in 
conjunction with the pathogens. 
Therefore, in this work, one of the basic questions was whether the environmental loads can 
cause disease (transformation disorders and processes) in the thyroid gland? In order to 
provide an answer, recognition of the disease, diagnostic typing and exploration of anamnesis 
relationships became necessary. 
Our aim was to develop the novel diagnostic method for environment-related thyroid diseases.  
 
Methods  
The grown thyroid-gland was classified by European Thyroid Association (ETA) and 
American Thyroid Association (ATA) methods (Table 1). 
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Table 1 Risk classification systems for thyroid diseases (SPECT/CT based)  





the tumor is unifocal 
T1 (≤ 1 cm) N0M0 
and there is no 
extension beyond the 
thyroid capsule 
low 
the tumor is T1 (> 1 cm) 
N0M0, or T2N0M0, or 
multifocal T1N0M0 
high 
the tumor is any T3; any 






no local or distant 
metastases; no tumor 
invasion of local 
regional tissues; no 
aggressive histology 
or vascular invasion 
intermediate risk 
microscopic invasion of 
the tumor into the 
perithyroidal tissue; 
cervical lymph node 








By these classifications of thyroid diseases were not examined in the anamneses the effects of 
environmental (exposure to ED compounds) medic status*. In the endocrine regulation 
network, the linkage of TSH, aTG, anti-TPO factors were not studied. The guide of the 
Endocrine Society was used for taking the patients’ medical history [5]. After the first medical 
examination, the patients (n=35) were diagnosed with thyroid dysfunction. In general, the 
laboratory test contains plasma hormone levels, hormone diurnal rhythm, U-hormones and 
their metabolites, stimulatory/inhibitory test and standard biochemistry in the examination 
method of endocrine disease. 
In the present work, the diagnostic protocol was supplemented with environmental health 
issues in which we studied occupation, workplace, place of residence, number of electric 
devices inside and outside the home, plastic items and exposure to chemicals.  
 
Determination of hormone and antibodies 
Whereas the usual microsomal antibody tests employ unpurified microsomes as an antigen 
preparation, the anti-TPO tests use a purified peroxidase. The two procedures are of 
comparable performance in terms of clinical sensitivity, but better lot-to-lot consistency and 
higher clinical specificity can be expected from anti-TPO tests due to the higher quality of the 
antigen used. Recombinant antigen and polyclonal anti-TPO antibodies are used in the 
Elecsys Anti-TPO assay. Measuring range is 5.00-600 IU/mL (defined by the lower detection 
limit and the maximum of the master curve). Values below the lower detection limit are 
reported as < 5.00 IU/mL. Values above the measuring range are reported as > 600 IU/mL. 
 
Immunoassay for the in vitro quantitative determination of antibodies to thyroglobulin in 
human serum and plasma. The anti-Tg determination is used as an aid in the detection of 
autoimmune thyroid diseases. The Elecsys Anti-Tg assay uses human antigen and monoclonal 
human anti-Tg antibodies. Measuring range is 10.0-4000 IU/mL (defined by the lower 
detection limit and the maximum of the master curve). Values below the lower detection limit 
are reported as< 10.0 IU/mL. Values above the measuring range are reported as> 4000 
IU/mL. 
 
The Elecsys TSH assay employs monoclonal antibodies specifically directed against human 
TSH. The antibodies labeled with ruthenium complex consist of a chimeric construct from 
human and mouse-specific components. As a result, interfering effects due to HAMA (human 
anti-mouse antibodies) are largely eliminated. Measuring range is 0.005-100 µIU/mL (defined 
by the lower detection limit and the maximum of the master curve). The functional sensitivity 
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is 0.014 µIU/mL. Values below the lower detection limit are reported as < 0.005 µIU/mL. 
Values above the measuring range are reported as > 100 µIU/mL (or up to 1000 µIU/mL for 
10-fold diluted samples). 
TSH, Anti-TPO and anti-TG were measured from serum using electrochemiluminescence 




Table 2 Parameters and classification (ATA, ETA) of thyroid cancer patients 






control     0,27-
4,29 
<115 <34 
1 AE 29 1 2 4.67 3298 >600 
2 BA 18 2 3 1,59 1125 242 
3 BB 18 2 3 2,32 24,51 10,35 
4 CSB 44 1 2 1,8 - 12,44 
5 CP 66 2 3 2,44 855 - 
6 DA 60 1 2 3,14 20,29 - 
7 DI 64 1 2 2,46 34,1 - 
8 DM 36 2 3 2,94 56,3 - 
9 FI 38 1 2 3,32  23,59 
10 HE 52 1 2 5,15 45,46 - 
11 HL 76 1 2 1,30 21,55 8,24 
12 HB 29 2 3 2,61 15,53 7,31 
13 JA 23 1 2 0,85 <10,10 - 
14 KS 43 2 3 3,28 704 - 
15 KG 54 2 3 0,96 238 - 
16 KAN 18 1 2 1,35 304,40 - 
17 KI 59 1 2 0,72 28,72 - 
18 MZS 50 1 2 1,38 46,16 - 
19 MA 42 2 3 1,81 367,80 - 
20 NN 32 1 2 1,11 - 17,87 
21 NBA 22 1 2 0,97 18 - 
22 RV 55 2 3 1,36 458,3 78,39 
23 SA 35 2 3 11,13 - 282 
24 SR 39 2 3 2,24 10,20 - 
25 SZJ 61 2 3 0,45 - 8,65 
26 SZI 77 1 2 0,68 10,47 - 
27 SZT 27 1 2 1,52 22,48 - 
28 TKM 40 1 2 1,44 38,4 - 
29 TFP 48 1 2 1,05 19,71 - 
30 TI 54 1 2 1,42 12,94 - 
31 TT 21 1 2 0,80 - 10,76 
32 TGYL 84 1 2 2,44 13,44 - 
33 VSG 38 2 3 6,24 - >600 
34 VM 59 1 2 3,2 13,72 - 
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Table 3 Increased inflammatory parameters (aTG, aTP) in thyroid cancer 
















control    0,27-
4,29 
<115 <34 <4.29/115  <4.29/34  
median 0,0353475 0,057794  
1 AE 29 4.67 3298 >600 0,00141* < 0,007789* 9 
2 BA 18 1,59 1125 242 0,00141* 0,00657* 8 
5 CP 66 2,44 855 - 0,002853* - 8 
14 KS 43 3,28 704 - 0,004659* - 8 
15 KG 54 0,96 238 - 0,004033* - 9 
16 KAN 18 1,35 304,40 - 0,004434* - 6 
19 MA 42 1,81 367,80 - 0,004921* - 8 
22 RV 55 1,36 458,3 78,39 0,002967* 0,017349* 7 
23 SA 35 11,13 - 282 - 0,039468* 8 
33 VSG 38 6,24 - >600 - < 0,0104* 6 
TSH: thyroid-stimulating hormone; aTG: antithyroglobulin antibody; aTPO: thyroperoxidase antibody 
*p<0.01 relation to the median 
 
Inflammatory parameters and factors derived from TSH data were always lower than the 
calculated median of control. At the same time, these results can be correlated with 
environmental health issues. 
 
Conclusions 
It is common for endocrine disrupting compounds to play an important role in inflammation 
at low doses, therefore it seems worthwhile to determine the inflammatory factors (aTG, 
aTPO) in addition to TSH in the case of thyroid dysfunction. It could be also important to find 
out the patients’ environmental exposition of endocrine disrupting compounds when taking 
anamnesis. 
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